
BDD Pharma
Eveloping and testing new drugs, particularly focusing on oral formulations and early-stage clinical trials.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor investor | €0.0 Valuation: €0.0 | round | |
investor investor investor | €0.0 Valuation: €0.0 | round | |
N/A | Seed | ||
Total Funding | 000k |
Related Content
BDD Pharma specializes in providing tailored oral drug delivery solutions, leveraging its proprietary time-controlled release platform, OralogiK. The company operates in the pharmaceutical sector, focusing on accelerating the market entry of drug formulations through its advanced clinical trial methodologies. BDD Pharma serves pharmaceutical companies seeking to enhance their drug delivery systems, particularly in the solid oral dose sector. The business model revolves around licensing agreements and partnerships, enabling clients to achieve rapid proof of concept and competitive advantage. Revenue is generated through bespoke service offerings and technology licensing. Key clients include top pharmaceutical companies looking for innovative solutions in drug formulation and delivery. BDD Pharma's commitment to scientific excellence and client-centric values positions it as a strategic partner in the pharmaceutical industry.
Keywords: drug delivery, OralogiK, clinical trials, pharmaceutical, licensing, time-controlled release, bespoke solutions, market entry, solid oral dose, partnerships.